BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage develop…
Biotechnology
US, Palo Alto [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 2392.55 | 1238.25 | -49.68 | |
| Graham Fair Price | -60.67 | 5.10 | 12.97 | |
| PEG | -49.02 | 0.48 | 0.94 | |
| Price/Book | 1.84 | -5.10 | -5.20 | |
| Price/Cash Flow | 56.89 | -24.24 | -56.23 | |
| Prices/Earnings | -263.21 | -38.03 | -10.47 | |
| Price/Sales | -99.37 | 25.38 | 4036.13 | |
| Price/FCF | 56.89 | -24.24 | -56.23 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 50.77 | 0.99 | 0.66 | |
| Operating Margin | -99.98 | 0.02 | -101.67 | |
| ROA | 86.53 | -0.04 | -0.31 | |
| ROE | 0.12 | 0.03 | -72.98 | |
| ROIC | -0.51 | < 0.005 | -98.93 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | 129.50 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.13 | 1.02 | 716.36 | |
| EPS QOQ | 0.11 | 0.79 | 612.50 | |
| FCF QOQ | 0.14 | -0.76 | 445.88 | |
| Revenue QOQ | -0.57 | 119.99 | 20823.33 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 2506.30 | 0.00 | inf | |
| Days Sales Outstanding (DSO) | 90.31 | 100.39 | 11.16 | |
| Inventory Turnover | 0.04 | 0.00 | inf | |
| Debt/Capitalization | 4.51 | 2.56 | -43.17 | |
| Quick Ratio | 3.04 | 5.34 | 75.88 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -7.76 | -5.87 | 24.34 | |
| Cash | 2.49 | 2.91 | 16.69 | |
| Capex | < 0.005 | < 0.005 | -234.84 | |
| Free Cash Flow | -0.72 | -1.24 | -72.27 | |
| Revenue | 0.01 | 1.18 | 11711.31 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad